DOCSLIB.ORG

New Phosphate Binding Agents: Ferric Compounds

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
New Phosphate Binding Agents: Ferric Compounds J Am Soc Nephrol 10: 1274–1280, 1999 New Phosphate Binding Agents: Ferric Compounds CHEN H. HSU, SANJEEVKUMAR R. PATEL, and ERIC W. YOUNG Nephrology Division, Department of Internal Medicine, University of Michigan Medical School, VA Medical Center, Ann Arbor, Michigan. Abstract. Several prior studies suggest that ferric compounds 0.058), 77.0 mg/d for the ferric citrate-treated group (P ϭ bind dietary phosphate and possess clinical potential as phos- 0.057), and 62.5 mg/d for the ferric chloride-treated group phate binding agents. Therefore, this study was conducted to (P Ͻ 0.002). Urinary phosphate excretion fell, sometimes to an measure the effect of several ferric compounds on intestinal even greater extent than did intestinal absorption, yielding no phosphate binding and absorption. Balance studies lasting 2 to net reduction in phosphate balance in these growing, young 4 wk were performed in normal and azotemic (achieved by animals with relatively preserved renal function. Calcium bal- subtotal nephrectomy) rats maintained on a 1.02% phosphorus ance was largely unaffected by the ferric compounds. There diet supplemented with ferric salts (formulated to 0.95% Fe) or were trends toward decreased serum phosphorus and parathy- no ferric salt (control). In rats with normal renal function roid hormone concentrations and increased iron and hematocrit (average creatinine clearance, 4.0 ml/min per kg), the average in the ferric-treated azotemic groups. All tested ferric com- net intestinal absorption of phosphate over all balance periods pounds were well tolerated, but animal growth was stunted in was 103.3 mg/d for the control group versus 84.7 mg/d for the the ferric chloride animals compared with the control group. ferric citrate group (P Ͻ 0.005). In the azotemic rats (average Phosphate binding was estimated at 85 to 180 mg per gram of creatinine clearance, 3.3 ml/min per kg), the average net intes- elemental iron, which is comparable to other phosphate bind- tinal absorption of phosphate over all balance periods was ing agents. Ferric salts decrease net intestinal phosphate ab- significantly lower for the three ferric groups than the control sorption and hold promise for the treatment of phosphate groups (P Յ 0.02): 95.3 mg/d for the control group versus 75.6 retention in patients with renal failure. mg/d for the ferric ammonium citrate-treated group (P ϭ In healthy individuals, phosphate is primarily eliminated by the retention, potentially exacerbating soft-tissue mineralization kidneys, which effectively regulate phosphate balance and the and organ dysfunction (6–10). blood phosphate concentration. Phosphate excretion is com- The problems associated with aluminum and calcium salts promised in patients with renal failure, resulting in systemic illustrate the need for new phosphate binding agents. Candidate phosphate retention and hyperphosphatemia. Phosphate reten- agents must be effective, safe, well tolerated, and relatively tion is a major toxic complication of renal failure, potentially inexpensive. Ferric compounds potentially fulfill these criteria. contributing to soft tissue mineral deposition, progression of Several human (11,12) and animal (13–16) studies from many renal disease, and secondary hyperparathyroidism (1–5). years ago strongly indicate that ferric compounds can bind Restriction of phosphate intake can potentially prevent hy- dietary phosphate and dramatically alter phosphate metabo- perparathyroidism and other toxic manifestations of phosphate lism. retention (2–5). However, dietary phosphate restriction alone is In view of these early reports, we performed studies in normal and azotemic rats designed to explore the efficacy and often insufficient to control hyperphosphatemia. Consequently, tolerability of ferric compounds as phosphate binders. Ferric most patients are treated with orally administered aluminum or citrate, ferric ammonium citrate, and ferric chloride were in- calcium salts that bind dietary phosphate and facilitate fecal vestigated. Our primary goal was to determine whether these elimination rather than intestinal absorption. Long-term use of compounds could bind dietary phosphate. We also examined aluminum compounds can cause bone and other toxicities; other aspects of mineral metabolism and animal viability. accordingly, calcium salts have become the phosphate binding agents of choice. However, calcium therapy can be compli- Materials and Methods cated by the development of hypercalemia and net calcium Phosphate Binding Effect of Ferric Citrate in Normal Rats Normal male Sprague Dawley rats (n ϭ 6) were fed a standard rat Received March 4, 1997. Accepted December 15, 1998. diet containing 1.02% phosphate (P) and 0.95% calcium (Ca) (ICN Correspondence to Dr. Chen H. Hsu, 3914 Taubman Center, Nephrology Biomedicals, Cleveland, OH) for 2 wk. The dietary phosphate content Division, University Hospital, Ann Arbor, MI 48109-0364. Phone: 313-936- was verified in our laboratory. An additional six normal male rats 9480; Fax: 313-936-9621; E-mail: [email protected] were fed the same diet supplemented with 4% ferric citrate for 2 wk. 1046-6673/1006-1274 All animals were housed in individual metabolic cages with a food Journal of the American Society of Nephrology container attached to the outside. Powdered food was used to prevent Copyright © 1999 by the American Society of Nephrology contamination of urine and stool. The animal was able to reach the J Am Soc Nephrol 10: 1274–1280, 1999 New Phosphate Binding Agents: Ferric Compounds 1275 food container but unable to bring food into the cage. Body weight, Table 1. Average weight, urinary creatinine excretion, and food consumption, urine output, and stool excretion were monitored blood measurements in rats with normal renal daily for 4 d per week for 2 wk. The daily stool and urine measure- functiona ments for each 4-d observation period were pooled and expressed as the average per day. Blood (1.5 ml) was taken from the tail vein of Parameter Control Ferric Citrate nonfasted rats in the morning (8 a.m. to 10 a.m.) each week for measurement of plasma phosphorus and creatinine. At the end of the Weight (g) study, blood was obtained from the aorta of anesthetized animals (also week 1 274 Ϯ 3 280 Ϯ 3 from 8 a.m. to 10 a.m.) for measurement of parathyroid hormone week 2 313 Ϯ 5 318 Ϯ 4 (PTH), calcitriol, and iron concentrations. Urine creatinine (mg/d) week 1 8.7 Ϯ 0.4 9.0 Ϯ 0.8 Phosphate Binding Effect of Ferric Compounds in Rats week 2 10.0 Ϯ 0.6 9.4 Ϯ 0.6 with Renal Failure Creatinine clearance (ml/min per kg) The phosphate binding effect of ferric compounds was also studied week 1 4.3 Ϯ 0.3 4.3 Ϯ 0.4 in Sprague Dawley rats with renal failure, achieved by subtotal week 2 3.9 Ϯ 0.2 3.7 Ϯ 0.2 nephrectomy. Two-thirds of one kidney was surgically removed by Blood values (week 2) arterial ligation, and the other kidney was removed through a flank Ϯ Ϯ incision 3 d later. The control group was fed the standard powdered rat PTH (pg/ml) 16 4163 Ϯ Ϯ diet containing 1.02% phosphate and 0.95% calcium. The other three calcitriol (pg/ml) 84 2822 groups of animals were fed the standard diet supplemented with one iron (␮g/ml) 1.8 Ϯ 0.2 1.7 Ϯ 0.1 of the following ferric compounds (Sigma Chemical Co., St. Louis, hematocrit (%) 49 Ϯ 148Ϯ 1 MO): 5% ferric ammonium citrate (molecular weight approximately a Ϯ 325 to 330 kD, 16.5 to 18.5% elemental Fe3ϩ), 4% ferric citrate Values are given as mean 1 SEM. PTH, parathyroid ⅐ hormone. (FeC6H5O7, 245 kD), or 4.4% ferric chloride (FeCl3 6H2O, 270 kD). Each ferric-containing diet was formulated to contain approximately 0.95% elemental iron. Body weight, food consumption, urine output, and stool excretion were monitored daily for 4 d per week over the 4-wk study period using the same techniques described for the rats with normal renal function. Daily measurements from each 4-d bal- ance period were averaged for each week of the study. Blood was taken once weekly for measurement of the plasma phosphorus and creatinine concentrations and at the end of the study for measurement of PTH, calcitriol, iron concentration, and hematocrit. Analytical Methods All phosphate determinations were measured and expressed as phosphorus. Stools were ashed at 800°C in a muffled furnace for 30 min, and phosphorus was extracted with 10% perchloric acid over- night before phosphorus measurement. Phosphorus and creatinine were measured as described previously (17). Plasma calcitriol was measured in duplicate according to the methods of Reinhardt et al. (18) and Hollis (19). The interassay coefficients of variation were 7.0% for the low control (20 pg/ml, n ϭ 12) and 4.1% for the high control (100 pg/ml, n ϭ 12). The intraassay coefficients of variation were 5.4% for the low control (n ϭ 6) and 4.7% for the high control. Calcitriol recovery averaged 65%. PTH was measured by immunora- diometric assay, using a rat PTH assay kit (Nichols Institute, Capist- rano, CA). The plasma iron concentration was measured using a Figure 1. Phosphate (left side) and calcium (right side) metabolism in commercial assay kit (Sigma Chemical Co.). rats with normal renal function. Average measurements shown for the 1- and 2-wk balance periods. Black bars indicate control animals and Statistical Analyses stippled bars indicate ferric citrate-treated animals. Data are shown as mean Ϯ 1 SEM. Statistical analyses were performed using repeated measures ANOVA for the rats with normal renal function. Data from the azotemic animals were analyzed using a mixed model to better accommodate repeated measurements, miss- ance in the two diet groups (control, ferric citrate) over the ing data values (see below), and random effects (20).
Load more

Recommended publications
  • Syllabus METAL ION EXCESS TOXICITY
    Syllabus Metalionexcesstoxicity-Feexcesstoxicity-Africansiderosis,hemosiderosis, hemochromatosis(bronzediabetes)anddetoxification.Cuexcesstoxicity:Wilson’sdisease andtreatment. Heavymetaliontoxicity:Hg,Pb,Cd,Astoxiceffects–mechanismoftoxiceffects.Heavy metaltoxicitytreatment-chelationtherapy:chelatingagentsforHg,Pb,Cd,Astoxicity. Metalcomplexesasdrugs:cis-plainasanticanceragent:mechanismofactionandside effects;goldcomplexesasantiarthriticdrugs-chrysotherapy.Metalcomplexesindiagnosis- Gdcomplexesinmagneticresonanceimaging(MRI). METALIONEXCESSTOXICITY Ironexcesstoxicity ü ItisduetoaccidentalintakeofFeSO4tabletscausingerosionofthegastrointestinal tract. ü Hemochomatosisisageneticdisorder,depositionofironoccursinvitalorganslike liver,spleen,pancreas,skinetc.Itleadstobronzepigmentationontheskiniscalled bronzediabetes. ü Siderosis(depositionofFeOdustinthelungs)isassociatedwithexcessofiron. ü AfricansiderosisisanironoverloaddisorderfirstobservedamongpeopleofSouthern AfricaandCentralAfrica.Dietaryironoverloadistheconsumptionoflargeamount ofhome-brewedbeerwithhighamountofironcontentinit. Detoxification : Siderophore desferrioxamine is a chelating antidote used for Fe removal Coppertoxicity Copper is a principal component of several metalloproteins and some naturally occurring pigments.Ahealthyadultpossessescopperbetween200to300mgandthehighestamountis concentratedin the locus of brain. Wilson’sdiseaseand Menkes’ kinky hair syndromeare associatedwithageneticdisorderinthemetabolismofcopper. Wilson’sdisease ü In Wilson'sdisease,the copper-content
    [Show full text]
  • Chelation Therapy
    Corporate Medical Policy Chelation Therapy File Name: chelation_therapy Origination: 12/1995 Last CAP Review: 2/2021 Next CAP Review: 2/2022 Last Review: 2/2021 Description of Procedure or Service Chelation therapy is an established treatment for the removal of metal toxins by converting them to a chemically inert form that can be excreted in the urine. Chelation therapy comprises intravenous or oral administration of chelating agents that remove metal ions such as lead, aluminum, mercury, arsenic, zinc, iron, copper, and calcium from the body. Specific chelating agents are used for particular heavy metal toxicities. For example, desferroxamine (not Food and Drug Administration [FDA] approved) is used for patients with iron toxicity, and calcium-ethylenediaminetetraacetic acid (EDTA) is used for patients with lead poisoning. Note that disodium-EDTA is not recommended for acute lead poisoning due to the increased risk of death from hypocalcemia. Another class of chelating agents, called metal protein attenuating compounds (MPACs), is under investigation for the treatment of Alzheimer’s disease, which is associated with the disequilibrium of cerebral metals. Unlike traditional systemic chelators that bind and remove metals from tissues systemically, MPACs have subtle effects on metal homeostasis and abnormal metal interactions. In animal models of Alzheimer’s disease, they promote the solubilization and clearance of β-amyloid protein by binding to its metal-ion complex and also inhibit redox reactions that generate neurotoxic free radicals. MPACs therefore interrupt two putative pathogenic processes of Alzheimer’s disease. However, no MPACs have received FDA approval for treating Alzheimer’s disease. Chelation therapy has also been investigated as a treatment for other indications including atherosclerosis and autism spectrum disorder.
    [Show full text]
  • Nr 1. Each Patient Suffering from Acute Coronary Syndrome Must Be Treated With
    SED - 3 - VERSION I February 2009 Nr 1. Each patient suffering from acute coronary syndrome must be treated with: A. Acetylsalicylic acid (ASA). B. ASA or clopidogrel. C. ASA and clopidogrel. D. depending on the type of myocardial infarction – ASA and clopidogrel or ASA only. E. depending on the mode of treatment (invasive vs noninvasive) – ASA and clopidogrel or ASA only. Nr 2. A patient in the class IV of Killip-Kimball classification has: A. pulmonary oedema. B. cardiogenic shock. C. blood retention (haemostasis) below the level of inferior angles of scapulae. D. no signs of heart insufficiency. E. chronic heart insufficiency, previously at least in NYHA class III. Nr 3. Schőnlein-Henoch purpura is a vasculitis that: A. is characterized by nephritic syndrome with cANCA antibodies. B. may present as rapidly progressive glomerulonephritis. C. is often accompanied by granulomas in the lungs. D. is typically treated by a surgical excision of granuloma. E. is typically treated by nephrectomy of the kidney with granulomas. Nr 4. Which of the below given drugs can cause hyperkalemia? 1) angiotensin converting enzyme inhibitors. 2) loop diuretics. 3) aldosterone antagonist. 4) thiazide. 5) indapamide. The correct answer is: A. 1,3. B. 1,2,3. C. 1,3,4. D. 1,3,5. E. all of the above. Nr 5. Which of the below is an absolute contraindication to thrombolytic therapy in acute myocardial infarction: A. age above 75. B. suspected dissecting aortic aneurysm. C. past cerebral stroke 2 years ago. D. high blood pressure >175/110 mmHg. E. invasive cardiology unit available on duty, which can be reached within 90 minutes.
    [Show full text]
  • Revisiting Hemochromatosis: Genetic Vs
    731 Review Article on Unresolved Basis Issues in Hepatology Page 1 of 16 Revisiting hemochromatosis: genetic vs. phenotypic manifestations Gregory J. Anderson1^, Edouard Bardou-Jacquet2 1Iron Metabolism Laboratory, QIMR Berghofer Medical Research Institute and School of Chemistry and Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia; 2Liver Disease Department, University of Rennes and French Reference Center for Hemochromatosis and Iron Metabolism Disease, Rennes, France Contributions: (I) Conception and design: Both authors; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: None; (VI) Manuscript writing: Both authors; (VII) Final approval of manuscript: Both authors. Correspondence to: Gregory J. Anderson. Iron Metabolism Laboratory, QIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, Queensland 4006, Australia. Email: [email protected]. Abstract: Iron overload disorders represent an important class of human diseases. Of the primary iron overload conditions, by far the most common and best studied is HFE-related hemochromatosis, which results from homozygosity for a mutation leading to the C282Y substitution in the HFE protein. This disease is characterized by reduced expression of the iron-regulatory hormone hepcidin, leading to increased dietary iron absorption and iron deposition in multiple tissues including the liver, pancreas, joints, heart and pituitary. The phenotype of HFE-related hemochromatosis is quite variable, with some individuals showing little or no evidence of increased body iron, yet others showing severe iron loading, tissue damage and clinical sequelae. The majority of genetically predisposed individuals show at least some evidence of iron loading (increased transferrin saturation and serum ferritin), but a minority show clinical symptoms and severe consequences are rare.
    [Show full text]
  • EASL Clinical Practice Guidelines: Wilson's Disease
    Clinical Practice Guidelines EASL Clinical Practice Guidelines: Wilson’s disease ⇑ European Association for the Study of the Liver Summary with acute liver failure. Wilson’s disease is not just a disease of children and young adults, but may present at any age [5]. This Clinical Practice Guideline (CPG) has been developed to Wilson’s disease is a genetic disorder that is found worldwide. assist physicians and other healthcare providers in the diagnosis Wilson’s disease is recognized to be more common than previ- and management of patients with Wilson’s disease. The goal is to ously thought, with a gene frequency of 1 in 90–150 and an inci- describe a number of generally accepted approaches for diagno- dence (based on adults presenting with neurologic symptoms sis, prevention, and treatment of Wilson’s disease. Recommenda- [6]) that may be as high as 1 in 30,000 [7]. More than 500 distinct tions are based on a systematic literature review in the Medline mutations have been described in the Wilson gene, from which (PubMed version), Embase (Dialog version), and the Cochrane 380 have a confirmed role in the pathogenesis of the disease [8]. Library databases using entries from 1966 to 2011. The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system used in other EASL CPGs was used and set against the somewhat different grading system used in the Clinical presentation AASLD guidelines (Table 1A and B). Unfortunately, there is not a single randomized controlled trial conducted in Wilson’s dis- The most common presentations are with liver disease or neuro- ease which has an optimal design.
    [Show full text]
  • Diagnosis and Treatment of Wilson Disease: an Update
    AASLD PRACTICE GUIDELINES Diagnosis and Treatment of Wilson Disease: An Update Eve A. Roberts1 and Michael L. Schilsky2 This guideline has been approved by the American Asso- efit versus risk) and level (assessing strength or certainty) ciation for the Study of Liver Diseases (AASLD) and rep- of evidence to be assigned and reported with each recom- resents the position of the association. mendation (Table 1, adapted from the American College of Cardiology and the American Heart Association Prac- Preamble tice Guidelines3,4). These recommendations provide a data-supported ap- proach to the diagnosis and treatment of patients with Introduction Wilson disease. They are based on the following: (1) for- Copper is an essential metal that is an important cofac- mal review and analysis of the recently-published world tor for many proteins. The average diet provides substan- literature on the topic including Medline search; (2) tial amounts of copper, typically 2-5 mg/day; the American College of Physicians Manual for Assessing recommended intake is 0.9 mg/day. Most dietary copper 1 Health Practices and Designing Practice Guidelines ; (3) ends up being excreted. Copper is absorbed by entero- guideline policies, including the AASLD Policy on the cytes mainly in the duodenum and proximal small intes- Development and Use of Practice Guidelines and the tine and transported in the portal circulation in American Gastroenterological Association Policy State- association with albumin and the amino acid histidine to 2 ment on Guidelines ; (4) the experience of the authors in the liver, where it is avidly removed from the circulation. the specified topic.
    [Show full text]
  • Practical Management of Iron Overload Disorder (IOD) in Black Rhinoceros (BR; Diceros Bicornis)
    animals Review Practical Management of Iron Overload Disorder (IOD) in Black Rhinoceros (BR; Diceros bicornis) Kathleen E. Sullivan, Natalie D. Mylniczenko , Steven E. Nelson Jr. , Brandy Coffin and Shana R. Lavin * Disney’s Animal Kingdom®, Animals, Science and Environment, Bay Lake, FL 32830, USA; [email protected] (K.E.S.); [email protected] (N.D.M.); [email protected] (S.E.N.J.); Brandy.Coffi[email protected] (B.C.) * Correspondence: [email protected]; Tel.: +1-407-938-1572 Received: 29 September 2020; Accepted: 26 October 2020; Published: 29 October 2020 Simple Summary: Black rhinoceros under human care are predisposed to Iron Overload Disorder that is unlike the hereditary condition seen in humans. We aim to address the black rhino caretaker community at multiple perspectives (keeper, curator, veterinarian, nutritionist, veterinary technician, and researcher) to describe approaches to Iron Overload Disorder in black rhinos and share learnings. This report includes sections on (1) background on how iron functions in comparative species and how Iron Overload Disorder appears to work in black rhinos, (2) practical recommendations for known diagnostics, (3) a brief review of current investigations on inflammatory and other potential biomarkers, (4) nutrition knowledge and advice as prevention, and (5) an overview of treatment options including information on chelation and details on performing large volume voluntary phlebotomy. The aim is to use evidence to support the successful management of this disorder to ensure optimal animal health, welfare, and longevity for a sustainable black rhinoceros population. Abstract: Critically endangered black rhinoceros (BR) under human care are predisposed to non-hemochromatosis Iron Overload Disorder (IOD).
    [Show full text]
  • Front Matter (PDF)
    HIGH RATE OF SUCCESS IN AN NIH-SPONSORED STUDY of hypertensive patients- the highest 83% withpercentageNORVASC#{174}- remained(amlodipineon initialbesylate)therapy after 4 years; nearly all patients were on the 5-mg starting dose’ LOW RATE OF DISCONTINUATION NY J50,oof(n=patients1730) discontinuedin placebo-controlledtherapy duestudiesto adverse effects2 PROVEN SAFETY No negative inotropic effects at clinical doses in hemodynamic studies2* No clinically significant effect on cardiac conduction or heart rate2 * Similar hemodynamic findings, however, have been observed with agents possessing significant negative inotropic effects. 5-mg and 10-mg tablets Once-Daily (amlodipinebesylate) EFFICACY AND SAFETY THAT’S EASY TO LIVE WITH Brief Summary NORVASC (amtodlpfne besylate) Tablets For Oral Use CONTRAINDICATIONS: NORVASC is conlraindicaled in palients wilh known sensitivity to amlodipine In hypertension WARNINGS: Increased Angina and/or Myocardlal Infarction: Rarely, patients, particularly those with severe obstructive coronary artery disease, have developed documented increased frequency, duration and/sr severity of angina or acute myscardiat infarction on starting calcium channel blocker therapy or atthe time of dosage increase The mechanism of this effect has not been elucidated. PRECAUTIONS: General: Since the vasodilation induced by NORVASC is gradual in onset, acute hypvtension has rarely been reported after oral administration of NORVASC. Nonetheless, caution should be evercised when admin- or angina,convenient istering NORVASC as with any other peripheral vasodilator particularly in patients with severe aortic stenosis. Use In Patients wIth CongestIve Heart FaIlure: In general, calcium channel blockers should be used with caution in patients with heart failure. NORVASC (5-10 mg per day) has been studied in a placebo-controlled trial of 1153 patients with NYHA Class Ill or IV heart failure vn stable doses of ACE inhibitor, digoxin.
    [Show full text]
  • Evaluating and Treating the Kidneys
    16_Nephrology.qxd 8/23/2005 10:41 AM Page 451 CHAPTER 16 Evaluating and Treating the Kidneys M. SCOTT ECHOLS, DVM, D ipl ABVP-A vian Renal diseases and their various classifications are well documented in the avian literature. The precise patho- genesis of avian renal disease, however, is not nearly as well described as it is in mammals. Renal disease has been shown to be fairly common in avian species. In studied poultry, as much as 29.6% of all disease condi- tions had abnormal pathology associated with or attrib- utable to renal disorders.20,214,251 Amyloidosis, urate nephrosis and gout were the most common diseases associated with mortality in a 4-year retrospective study conducted at a waterfowl park in Ontario, Canada.210 Thirty-seven percent of all avian cases presenting with renal tissue for histopathological examination, included over a 15-month period at the Schubot Exotic Bird Health Center, had one or more histologically identified kidney lesions.187 Nine of 75 pheasants (Phasianus colchicus) died with nephritis, one or both ureters impacted, and visceral gout in another comprehensive study on avian mortality.186 These case reports and retro- spective studies support the conclusion that renal dis- eases are relatively common and are clinically significant in multiple avian species. When compared to mammalian counterparts, the avian urogenital system has many structural and functional differences, which have been described previously.77,90,118,181,187,227 Differences including gross anatomy, renal portal blood flow and protein waste elimination should be considered when reviewing this chapter, as findings obtained from mammalian studies may not necessarily be applicable to birds.
    [Show full text]
  • Cardiac Impairment Due to Hypocalcemia in a Multitransfused Patient with Thalassemia Major S Ansari, a Kiumarsi, T Rostami
    The Internet Journal of Hematology ISPUB.COM Volume 10 Number 1 Cardiac Impairment Due To Hypocalcemia In A Multitransfused Patient With Thalassemia Major S Ansari, A Kiumarsi, T Rostami Citation S Ansari, A Kiumarsi, T Rostami. Cardiac Impairment Due To Hypocalcemia In A Multitransfused Patient With Thalassemia Major. The Internet Journal of Hematology. 2014 Volume 10 Number 1. Abstract We report a case of a 16-year-old Iranian girl with transfusion-dependent thalassemia major who presented with chest pain. Laboratory investigations showed marked hypocalcemia, hypomagnesaemia, hyperphosphatemia, and an extremely low vitamin D3 level. She had a low parathyroid hormone (PTH) level. She was refractory to calcium and magnesium supplementation. However, she responded to oral cacitriol. She was diagnosed to have hypoparathyroidism most likely due to iron overload due to multitransfusions and vitamin D3 deficiency. Vitamin D3 deficiency most likely was independent of iron overload. Cardiomyopathy in this patient could have been secondary to iron overload and/or hypocalcemia. Hypocalcemia could have been due to hypoparathyroidism and/or the low vitamin D3 level. Her response to calcitriol but not to calcium and magnesium supplementation suggests that the hypocalcemia was due to hypoparathyroidism and/or vitamin D3 deficiency. The response to calcitriol also indicates that iron overload was not responsible since cardiac impairment due to iron overload would be refractory to calcitriol treatment. Cardiac failure in multitransfused patients is usually ascribed to hemosiderosis. This case demonstrates that hypocalcemia related to vitamin D3 insufficiency also can cause myocardial dysfunction. Patients with thalassemia minor should be periodically screened for calcium and vitamin D3 levels to avoid complications secondary to hypocalcemia.
    [Show full text]
  • Nutrition Journal of Parenteral and Enteral
    Journal of Parenteral and Enteral Nutrition http://pen.sagepub.com/ Micronutrient Supplementation in Adult Nutrition Therapy: Practical Considerations Krishnan Sriram and Vassyl A. Lonchyna JPEN J Parenter Enteral Nutr 2009 33: 548 originally published online 19 May 2009 DOI: 10.1177/0148607108328470 The online version of this article can be found at: http://pen.sagepub.com/content/33/5/548 Published by: http://www.sagepublications.com On behalf of: The American Society for Parenteral & Enteral Nutrition Additional services and information for Journal of Parenteral and Enteral Nutrition can be found at: Email Alerts: http://pen.sagepub.com/cgi/alerts Subscriptions: http://pen.sagepub.com/subscriptions Reprints: http://www.sagepub.com/journalsReprints.nav Permissions: http://www.sagepub.com/journalsPermissions.nav >> Version of Record - Aug 27, 2009 OnlineFirst Version of Record - May 19, 2009 What is This? Downloaded from pen.sagepub.com by Karrie Derenski on April 1, 2013 Review Journal of Parenteral and Enteral Nutrition Volume 33 Number 5 September/October 2009 548-562 Micronutrient Supplementation in © 2009 American Society for Parenteral and Enteral Nutrition 10.1177/0148607108328470 Adult Nutrition Therapy: http://jpen.sagepub.com hosted at Practical Considerations http://online.sagepub.com Krishnan Sriram, MD, FRCS(C) FACS1; and Vassyl A. Lonchyna, MD, FACS2 Financial disclosure: none declared. Preexisting micronutrient (vitamins and trace elements) defi- for selenium (Se) and zinc (Zn). In practice, a multivitamin ciencies are often present in hospitalized patients. Deficiencies preparation and a multiple trace element admixture (containing occur due to inadequate or inappropriate administration, Zn, Se, copper, chromium, and manganese) are added to par- increased or altered requirements, and increased losses, affect- enteral nutrition formulations.
    [Show full text]
  • Case Report Endocrine Societies Hypoparathyroidism in a Case of Transfusion Dependent Thalassemia
    Journal of the ASEAN Federation of Case Report Endocrine Societies Hypoparathyroidism in a Case of Transfusion Dependent Thalassemia Anirban Majumder1 and Sagar Basu2 1Endocrinology Department, KPC Medical College, West Bengal University of Health Sciences, Kolkata, India 2Neurology Department, KPC Medical College, West Bengal University of Health Sciences, Kolkata, India Abstract Repeated blood transfusions in transfusion dependent thalassemia (TDT) leads to iron overload-related endocrine complications. Hypoparathyroidism (HPT) with severe signs of hypocalcemia is a recognized complication among these patients. A 14-year-old thalassaemic boy, on regular transfusion and on anticonvulsant therapy with a presumptive diagnosis of epilepsy for the last 1 year, was admitted with high fever and severe muscle cramps with positive Trousseau’s sign. He was diagnosed as a case of primary HPT and magnesium deficiency on the basis of low serum calcium, high phosphate, normal alkaline phosphates, very low intact parathyroid hormone (iPTH), normal serum vitamin D and very low serum magnesium level. His calcium, magnesium and phosphate level normalised following treatment with intravenous magnesium and calcium. His iPTH improved but remained at low normal. He was discharged from hospital with oral calcium, calcitriol, and magnesium supplementation. The anticonvulsant (Phenobarbitone) was successfully withdrawn gradually over the next six months without any recurrence of seizure in the subsequent 3 years of follow up. Acquired HPT (apparently from hemosiderosis) is a common cause of hypocalcemia; and magnesium depletion further complicated the situation leading to severe hypocalcemia with recurrent episodes of convulsion. Magnesium replacement improved the parathyroid hormone (PTH) value proving its role in acquired HPT. Very high phosphate level on admission and poor PTH response with respect to the low serum calcium, indicates intrinsic parathyroid pathology.
    [Show full text]